Related Experiment Video
Updated: Jun 26, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
[Coagulative hemostasis in patients with acute viral myocarditis]
Insights
This study reveals that various blood markers, including fibrinogen parameters and platelet aggregation, correlate with the severity of acute virus myocarditis. These findings highlight the need for medication to correct these imbalances.
Area of Science:
- Cardiology
- Hematology
- Virology
Context:
- Acute virus myocarditis presents with complex pathophysiological changes.
- Understanding these changes is crucial for effective patient management.
- Existing literature lacks comprehensive correlation between specific hematological markers and myocarditis severity.
Purpose:
- To investigate the correlation between a wide range of hematological and hemostatic parameters and the clinical severity of acute virus myocarditis.
- To establish statistically reliable links between specific biomarkers and disease grades.
Summary:
- This study established statistically significant correlations between fibrinogen parameters, dissolved complexes of monomeric fibrinogen (DCMF), fibrinogen/fibrin degradation products (FDP), platelet aggregation (first and second waves), activated partial thromboplastin time (APPT), range index of contact platelet activation (RICPA), general index of thrombophilia (GIT), platelet count, prothrombin time (PT), heparin in blood, plasma tolerance to heparin (PTH), euglobulin clot lysis time (TLEC), lipid peroxidation, antioxidant enzymes like superoxide dismutase (SOD), and the clinical severity of acute virus myocarditis.
- These correlations were observed across three defined groups of disease severity.
- The identified correlations indicate that these parameters are reliable indicators of disease progression and require therapeutic intervention.
Impact:
- Provides novel insights into the hematological profile of acute virus myocarditis patients.
- Establishes a basis for utilizing specific blood markers in assessing disease severity and guiding treatment strategies.
- Suggests that targeted pharmacological correction of identified hematological abnormalities may improve patient outcomes in acute virus myocarditis.
Abstract:
For the first time it was established that changes of fibrinogen parameters, dissolved complexes of monomeric fibrinogen (DCMF), products of fibrinogen degradation (PDEF), first and second waves of platelet aggregation, activated partial platelet time (APPT), range index of contact platelet activation (RICPA), general index of thrombophilia (GIT), platelets, prothrombin time, heparin in blood, plasma tolerance to heparin (PTH), time lysis and euglobulin clot (TLEC), lipid peroxidation, antiradical defence ferment, superoxiddismutase (SOD) in patients with acute virus myocarditis of first, second and third group of severity correlate statistically reliably with grade of severity of clinical course of the disease and require correction with medications.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Acute Coronary Syndrome III: Diagnostic Studies